Alvaradohay1073

In this way, we can produce biodegradable NPs with a perfume loading up to 85 % w/w without the need for additional surfactants. Subsequently we show that the ionizable group is able to confer a positive charge to our nanoparticles and, in turn, a high adsorption capacity on natural fibers (i.e. hairs and cotton fabric). Finally, we demonstrate the nanoparticle resistance to rinsing and their ability to confer a long-lasting fragrance perception to treated hair swatches for at least 3 weeks. The emulsion stability depends on the physicochemical properties of the dispersed phase and their interaction with the continuous phase. Surface-active compounds (SAC) are added in emulsions to reduce the interfacial tension (IT) between these phases and keep the oil droplets stabilized. Moreover, small amounts of SAC can occupy intermolecular voids in the dried matrix, reducing the oxidation. However, the formulation must reflect a trade-off between protection and emulsion stabilization. Therefore, this work aimed to identify the minimum concentration of SAC (modified starch-MS, gelatin-GE, and whey protein isolate-WPI) ranging from 0.48 to 6 % (w/w) to form and stabilize droplets of an unsaturated triglyceride (fish oil-FO) or a volatile oil (orange essential oil-OEO). GE did not change the IT (6.7 mN/m) and stabilized the emulsions only through an increase of the viscosity (∼42 mPas for FO-emulsions and ∼97 mPas for OEO-emulsions), presenting high droplet size (∼10 μm) and low surface charge (∼1.5 mV). WPI reduced the IT to a limit value (4.5 mN/m at 1.2 % w/w for OEO and 5.3 mN/m at 2.4 % w/w for FO), whereas MS reduce constantly the IT with the increase of the concentration for both oils (∼4.2 mN/m at 6 % w/w). Both WPI and MS-emulsions presented similar droplet size (∼2.0 μm), but WPI presented higher surface charge of WPI-emulsions (-45 mV) than MS-emulsions (-30 mV). This study allowed to gain a consistent understanding of structure-property relationships on the use of SAC in emulsions. Among strontium-based drugs, the Strontium ranelate (SrR) is a divalent strontium salt of ranelic acid which has an overall effect over the bone microarchitecture improvement. However, some findings reveal that the SrR affects in an opposite manner to the cell proliferation and osteoblastic differentiation, based on its concentration. Consequently, its release should be controlled. The incorporation of Halloysite nanotubes (HNT) as nanocarriers of SrR, into gelatine (GN) coatings, tailors the release of this anabolic bone-forming and anti-catabolic agent to stimulate bone growth. In fact, as-prepared GN/HNT-SrR coatings release 100 % SrR in phosphate buffered saline (PBS) within 21 days, and cellular studies of the nanocomposite coatings (MTT, Alkaline Phosphatase activity (ALP) and Calcium deposition assay) confirm the valuable bio-performance of these composite coatings to enhanced bone regeneration. In the present manuscript, suspensions with HNT/GN weight ratio of 0.5 are formulated to coat AISI 316 L stainless steel foils by Electrophoretic Deposition (EPD). Zeta potential determination is used to stablish the drug loading (HNT-SrR) by electrostatic interaction, as well as to optimize the dispersion of bare HNT and HNT SrR-loaded in a GN aqueous solution. Polyethilenimnine (PEI) is used as stabilizer to buffer the suspension media, assure cargo-drug dispersion and sequential release, while the thermal gelling of the suspension controls and step up the coating formation during EPD. In this work, dual drug loaded in chitosan/dextran sulfate/chitosan (CS/DEX/CS) nanoparticles was synthesized by layer-by-layer (LBL) self-assembly technique for use in anti-cancer drug delivery. The nanoparticles were characterized in terms of particle size, zeta-potential, encapsulation efficiency and morphology (SEM and TEM). The in vitro release of the dual drugs, inner PTX and outer 5-Fu, from the CS-PTX/EX/CS-5Fu nanoparticles with different numbers of CS and DEX layers and different PBS was characterized. The results revealed that the pH-sensitive dual drug loaded nanoparticles exhibited a controlled release profile, and the release mechanism followed Two-phase kinetic model for PTX and Higuchi model for 5-Fu. Subsequently the cytotoxicity of nanoparticles was evaluated against HepG2 cells using MTT and apoptosis assay, resulting in synergistic effects between dual drugs and enhanced inhibition to cancer cells. Cellular uptake studies demonstrated efficient internalization of PTX and 5-Fu in HepG2 cells. Therefore the dual drug loaded CS/DEX/CS nanoparticles had good prospects for the biomedical delivery application. For cancer treatment, intratumoral drug injection has many limitations and not commonly adopted. The poly[lactic-co-glycolic acid] (PLGA) has emerged as a promising vehicle to enhance the in vitro/in vivo characteristic of various drugs. We prepared doxorubicin-PLGA microspheres (DOX-PLGA MSs) using the electrospray method. An in vitro elution method was employed to evaluate the release of DOX from the MSs. We performed an in vivo study on rats, in which we directly injected DOX-PLGA MSs into the liver. We measured liver and plasma DOX concentrations to assess local retention and systemic exposure. The mean diameter of the MSs was 6.74 ± 1.01 μm. The in vitro DOX release from the MSs exhibited a 12.3 % burst release on day 1, and 85.8 % of the drug had been released after 30 days. The in vivo tests revealed a higher local drug concentration at the target lobe of the liver than at the adjacent median lobe. In the first week, the DOX concentration in the peripheral blood of the MS group was lower than that of the direct DOX injection group. Based on the measured intrahepatic concentration and plasma pharmacokinetic profiles, DOX-PLGA MSs could be suitable vectors of chemotoxic agents for intratumoral injection. Background Argentina is considered a region of low seroprevalence of hepatitis E virus (HEV), however; no studies have evaluated its burden among acute hepatitis cases. OBJECTIVES We aimed to estimate the proportion of acute HEV and outcome in a cohort of patients with acute hepatitis from 6 liver units in the Metropolitan area of Buenos Aires (MABA). Stem Cells agonist STUDY DESIGN We performed a prospective cohort study including patients ≥18 years with acute hepatitis (increase in transaminases x 5 ULN) fromJuly 2016 to May 2018. Severe hepatitis was defined as acute hepatitis + INR> 1.5 and acute liver failure as severe hepatitis + encephalopathy. In patients in whom other etiologies were excluded, HEV tests were performed anti-HEV IgM/G and HEV-RNA in serum and feces. RESULTS Overall, 268 patients with acute hepatitis were included in the study. The most frequent etiologies of acute hepatitis were hepatitis B (67patients, 25 %), hepatotoxicity (65, 24 %) and autoimmune hepatitis (26, 10 %). Acute HEV infection was confirmed in 8 (2.